Association of tumor mutation burden and epidermal growth factor receptor inhibitor history with survival in patients with metastatic stage III/IV nonsmall-cell lung cancer: A retrospective study. Clinics, [S. l.], v. 76, p. e2251, 2021. DOI: 10.6061/clinics/2021/e2251. Disponível em: https://www.revistas.usp.br/clinics/article/view/192286.. Acesso em: 27 apr. 2024.